| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969412 | B BRAUN MEDICAL INC | Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture |
Sep, 2026
(2 years from now) | |
| US9504666 | B BRAUN MEDICAL INC | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Dec, 2033
(9 years from now) | |
Clorotekal is owned by B Braun Medical Inc.
Clorotekal contains Chloroprocaine Hydrochloride.
Clorotekal has a total of 2 drug patents out of which 0 drug patents have expired.
Clorotekal was authorised for market use on 26 September, 2017.
Clorotekal is available in solution;intrathecal dosage forms.
Clorotekal can be used as a method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl.
The generics of Clorotekal are possible to be released after 11 December, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2020 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 September, 2017
Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing ...
Dosage: SOLUTION;INTRATHECAL
CLOROTEKAL family patents
